New compound https://www.bioworld.com/rss en-us New LRH-1 antagonists exhibit antitumor activity in prostate cancer models http://www.bioworld.com/articles/730171 Tue, 07 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730171-new-lrh-1-antagonists-exhibit-antitumor-activity-in-prostate-cancer-models 3D illustration showing tumor inside prostate gland and closeup view of cancer cells BRD9 PROTAC shows efficacy in sarcoma and leukemia models http://www.bioworld.com/articles/730016 Mon, 30 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730016-brd9-protac-shows-efficacy-in-sarcoma-and-leukemia-models Art concept for hematologic cancer Selective PARP1 inhibitor disclosed http://www.bioworld.com/articles/729935 Thu, 26 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729935-selective-parp1-inhibitor-disclosed Illustration of cancer cell in crosshairs being destroyed MMV-1581361 combines strong antimalarial efficacy with transmission blockade PfATP4 inhibitor, and its efficacy in models of malaria. The compound originates from MMV-020136, following structure-activity relationship studies to optimize antimalarial activity.]]> http://www.bioworld.com/articles/729934 Thu, 26 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729934-mmv-1581361-combines-strong-antimalarial-efficacy-with-transmission-blockade Release of malaria parasites from red blood cell HX-16108 holds promise for treating inflammatory skin diseases http://www.bioworld.com/articles/729592 Wed, 11 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729592-hx-16108-holds-promise-for-treating-inflammatory-skin-diseases Skin irritation on hands Dual degrader shows activity in acute myeloid leukemia models http://www.bioworld.com/articles/729325 Wed, 04 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729325-dual-degrader-shows-activity-in-acute-myeloid-leukemia-models Microscopic image of acute myeloid leukemia (AML) cells. Acute myeloid leukemia cells. Credit: Cincinnati Children's Newly described selective CDK6 degrader exhibits potential in leukemia models http://www.bioworld.com/articles/729154 Tue, 03 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729154-newly-described-selective-cdk6-degrader-exhibits-potential-in-leukemia-models Leukemia illustration New compound against tumors with aberrant FGFR2 signaling http://www.bioworld.com/articles/728919 Wed, 18 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728919-new-compound-against-tumors-with-aberrant-fgfr2-signaling CZL-077 shows robust preclinical antitumor activity http://www.bioworld.com/articles/728887 Mon, 16 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728887-czl-077-shows-robust-preclinical-antitumor-activity Vials, syringes, and pills New CDK12/13 dual degrader for TNBC http://www.bioworld.com/articles/728815 Thu, 12 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728815-new-cdk12-13-dual-degrader-for-tnbc Illustration of tumor in breast SY-589 suppresses HR-deficient tumors via POLθ inhibition http://www.bioworld.com/articles/728630 Thu, 05 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728630-sy-589-suppresses-hr-deficient-tumors-via-pol-inhibition Thiazole derivatives show drug-like properties as broad-spectrum antirhinovirus agents http://www.bioworld.com/articles/728455 Mon, 02 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728455-thiazole-derivatives-show-drug-like-properties-as-broad-spectrum-antirhinovirus-agents Illustration of rhinovirus particles Centessa’s CNT-9982 shows promise for MDD http://www.bioworld.com/articles/728187 Wed, 21 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/728187-centessas-cnt-9982-shows-promise-for-mdd Orum’s ORM-1153 outperforms venetoclax in AML http://www.bioworld.com/articles/727444 Wed, 24 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/727444-orums-orm-1153-outperforms-venetoclax-in-aml A PROTAC degrader of RIPK1 with better drug properties http://www.bioworld.com/articles/726850 Fri, 05 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/726850-a-protac-degrader-of-ripk1-with-better-drug-properties Molecular research art concept PARP-ATR dual inhibitor shows preclinical activity against TNBC http://www.bioworld.com/articles/726700 Tue, 02 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/726700-parp-atr-dual-inhibitor-shows-preclinical-activity-against-tnbc Scientist looking in microscope, chemical structure concept image Novel PROTAC based on GDC-0810 against ER-positive breast cancer http://www.bioworld.com/articles/726588 Thu, 27 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726588-novel-protac-based-on-gdc-0810-against-er-positive-breast-cancer Breast cancer cell Breast cancer cell. Credit: Bruce Wetzel and Harry Schaefer, NCI New FGFR3 inhibitors offer best-in-class selectivity, potency http://www.bioworld.com/articles/726572 Wed, 26 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726572-new-fgfr3-inhibitors-offer-best-in-class-selectivity-potency Bladder Selective CDK2 inhibitor is active in multiple solid tumor models http://www.bioworld.com/articles/726528 Mon, 24 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726528-selective-cdk2-inhibitor-is-active-in-multiple-solid-tumor-models Targeted cancer cell Small-molecule SMARCA2 inhibitors to treat SMARCA4-mutant cancers http://www.bioworld.com/articles/726526 Mon, 24 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726526-small-molecule-smarca2-inhibitors-to-treat-smarca4-mutant-cancers Novel B7-H7-targeted ADC NPX-125 active in solid tumors http://www.bioworld.com/articles/726413 Fri, 21 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726413-novel-b7-h7-targeted-adc-npx-125-active-in-solid-tumors CEACAM5-targeting ADC with a highly potent pan-RAS(ON) inhibitor payload http://www.bioworld.com/articles/726287 Tue, 18 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726287-ceacam5-targeting-adc-with-a-highly-potent-pan-rason-inhibitor-payload Floating antibody drug conjugates Small-molecule p53 Y220C reactivators with enhanced potency presented http://www.bioworld.com/articles/726285 Tue, 18 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726285-small-molecule-p53-y220c-reactivators-with-enhanced-potency-presented Novel <em>bis</em>-heterocyclic PRMT inhibitors against TNBC http://www.bioworld.com/articles/726086 Mon, 17 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726086-novel-embis-em-heterocyclic-prmt-inhibitors-against-tnbc Illustration of tumor in breast New oral KRAS G12C(ON) and G12V(ON) inhibitors presented http://www.bioworld.com/articles/726019 Wed, 12 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726019-new-oral-kras-g12con-and-g12von-inhibitors-presented Oral CBL-B inhibitor shows strong immune activation, favorable safety http://www.bioworld.com/articles/726018 Wed, 12 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726018-oral-cbl-b-inhibitor-shows-strong-immune-activation-favorable-safety Cancer immunotherapy illustration TRI-611 targets ALK fusion and TKI-resistant NSCLC http://www.bioworld.com/articles/726061 Tue, 11 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726061-tri-611-targets-alk-fusion-and-tki-resistant-nsclc Illustration of lungs with cancer inset ZE77-0273 shows broad activity against EGFR resistance mutations in NSCLC http://www.bioworld.com/articles/725930 Mon, 10 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725930-ze77-0273-shows-broad-activity-against-egfr-resistance-mutations-in-nsclc 3D illustration and light micrograph of lung cancer. Discovery of PSTA-2413, a potential best-in-class oral pan-RAS inhibitor http://www.bioworld.com/articles/725929 Mon, 10 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725929-discovery-of-psta-2413-a-potential-best-in-class-oral-pan-ras-inhibitor Tango’s first-in-class HBS1L/PELO degrader for FOCAD-deleted cancers http://www.bioworld.com/articles/725736 Fri, 31 Oct 2025 09:00:00 -0400 https://www.bioworld.com/articles/725736-tangos-first-in-class-hbs1l-pelo-degrader-for-focad-deleted-cancers AI generated, 3D rendering of protein degradation